Prognostic implications of FGFR1 and MYC status in esophageal squamous cell carcinoma

Table 1 Clinicopathological characteristics of patients with esophageal squamous cell carcinoma

Variables		n (%)
Age (yr)	≤ 60	46 (25.6)
	> 60	134 (74.4)
Sex	Male	169 (93.9)
	Female	11 (6.1)
Smoking	No	28 (15.6)
	Yes	151 (84.4)
Histological grade	WD	35 (19.4)
	MD	119 (66.1)
	PD and basaloid	26 (14.4)
Localization	Upper	7 (3.9)
	Middle	44 (24.9)
	Lower	116 (65.5)
	EGJ	10 (5.6)
T	1a	16 (8.9)
	1b	65 (36.1)
	2	17 (9.4)
	3	78 (43.3)
	4	4 (2.2)
N	0	92 (51.1)
	1	52 (28.9)
	2	29 (16.1)
	3	7 (3.9)
Stage	IA	14 (7.8)
	IB	49 (27.2)
	IIA	21 (11.7)
	IIB	32 (17.8)
	IIIA	37 (20.6)
	IIIB	19 (10.6)
	IIIC	8 (4.4)
Adjuvant therapy	No	112 (67.8)
	Yes	58 (32.2)
FGFR1 amplification	No amplification	136 (78.6)
	Low amplification	3 (1.7)
	High amplification	34 (19.7)
MYC amplification	No amplification	77 (45.9)
	Low amplification	20 (11.9)
	High amplification	71 (42.3)
MYC expression	0 (none)	74 (41.1)
	1 (weak)	54 (30.0)
	2 (moderate)	41 (22.8)
	3 (strong)	11 (6.1)

FGFR1: Fibroblast growth factor receptor 1; WD: Well differentiated; MD: Moderately differentiated; PD: Poorly differentiated; EGJ: Esophagogastric junction.